| Sep 17 |
Rocket Pharma gains on trial update for gene therapy
|
| Sep 17 |
Rocket Pharmaceuticals Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease
|
| Sep 15 |
Rocket Pharmaceuticals: 2 Gene Therapy Candidates Anticipating Near-Term Review
|
| Sep 10 |
Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of Directors
|
| Sep 9 |
Rocket Stock Down More Than 30% in Past Six Months: Here's Why
|
| Sep 4 |
Rocket Pharmaceuticals (RCKT) Down 10.6% Since Last Earnings Report: Can It Rebound?
|
| Aug 27 |
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
|
| Aug 25 |
Morgan Stanley Predicts up to 220% Jump for These 2 ‘Strong Buy’ Stocks
|
| Aug 5 |
Rocket Pharmaceuticals GAAP EPS of -$0.74 misses by $0.02
|
| Aug 5 |
Rocket Pharmaceuticals: Q2 Earnings Snapshot
|
